Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 4/20 | 0.52 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
| ▸ | AHCY | P23526 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobucavir SCHEMBL598707 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL5990162 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL10460499 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL51919 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL9615453 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL9615451 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL15630215 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL51918 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL7699733 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL7166488 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569931-B1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | claimed |
| US-20080194523-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | claimed |
| US-20080194554-A1 | Hiv Protease Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | claimed |
| EP-1569933-B1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1569934-B1 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-01-23 | — | — | EP | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2000016754-A2 | ANTIVIRAL COMBINATIONS COMPRISING LAMIVUDINE AND LOBUCAVIR | GLAXO GROUP LIMITED (GB) | 2000-03-30 | — | — | WO | claimed |
| US-5879700-A | TREATING HERPES VIRUS INFECTIONS | HOSTETLER KARL Y (US) | 1999-03-09 | — | — | US | claimed |
| EP-0433897-B1 | Process for preparing an optically active cyclobutane nucleoside | SQUIBB & SONS INC (US) | 1997-10-01 | — | — | EP | claimed |
| EP-0335355-B1 | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines | SQUIBB & SONS INC (US) | 1997-10-01 | — | — | EP | claimed |
| EP-0736533-A1 | Intermediates and process for the preparation of an antiviral agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0535448-B1 | Process and intermediates for the preparation of an antiviral agent containing a cyclobutyl group | SQUIBB & SONS INC (US) | 1996-06-26 | — | — | EP | claimed |
| EP-0579421-A2 | Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process | E.R. Squibb & Sons, Inc. (US) | 1994-01-19 | — | — | EP | claimed |
| EP-0535448-A2 | Process and intermediates for the preparation of an antiviral agent containing a cyclobutyl group | E.R. SQUIBB & SONS, INC. (US) | 1993-04-07 | — | — | EP | claimed |
| US-5064961-A | PROCESS FOR PREPARING AN OPTICALLY ACTIVE CYCLOBUTANE NUCLEOSIDE | E. R. SQUIBB & SONS, INC. (US) | 1991-11-12 | — | — | US | claimed |
| EP-0433897-A2 | Process for preparing an optically active cyclobutane nucleoside | E.R. SQUIBB & SONS, INC. (US) | 1991-06-26 | — | — | EP | claimed |
| EP-0335355-A2 | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines | E.R. Squibb & Sons, Inc. (US) | 1989-10-04 | — | — | EP | claimed |
| JP-5178857-A | — | — | None | — | — | JP | disclosed |
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | CHIMERIX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20170273994-A1 | Compositions and Methods for Combination Antiviral Therapy | GILEAD SCIENCES, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9765100-B2 | Nucleoside phosphonate salts | CHIMERIX, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-3216789-A1 | METHODS OF TREATING VIRAL INFECTION | Chimerix, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9744181-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170232019-A1 | Compositions and Methods for Combination Antiviral Therapy | GILEAD SCIENCES INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9694024-B2 | Methods of treating retroviral infections and related dosage regimes | CHIMERIX, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2534150-B1 | METHODS OF TREATING VIRAL INFECTION | CHIMERIX INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3085377-A1 | METHODS OF TREATING VIRAL INFECTIONS | Chimerix, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9457036-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160158259-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | CHIMERIX, INC. | 2016-06-09 | — | — | US | disclosed |
| EP-3025718-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9278135-B2 | Methods of treating retroviral infections and related dosage regimes | CHIMERIX INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2254582-B1 | METHODS OF TREATING VIRAL INFECTIONS | CHIMERIX INC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150203519-A1 | NUCLEOSIDE PHOSPHONATE SALTS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2015-07-23 | — | — | US | disclosed |
| US-20150111856-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111855-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-9006218-B2 | Nucleoside phosphonate salts | CHIMERIX INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8993542-B2 | Methods of treating viral infections | CHIMERIX INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140213556-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8716264-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-1556393-B1 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130072460-A1 | Methods Of Treating Retroviral Infections And Related Dosage Regimes | CHIMERIX, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130035313-A1 | Nucleoside Phosphonate Salts | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2013-02-07 | — | — | US | disclosed |
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| US-7928095-B2 | DNA topoisomerase I inhibitors; anticancer agents | ENZON PHARMACEUTICALS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110021464-A1 | METHODS OF TREATING VIRAL INFECTIONS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2011-01-27 | — | — | US | disclosed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196453-A1 | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents | Cellvir (FR) | 2010-06-16 | — | — | EP | disclosed |
| US-7498320-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090036408-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-7462608-B2 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1583542-B9 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1742642-B1 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080194554-A1 | Hiv Protease Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080193408-A1 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ENZON PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| EP-1583542-B1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080139496-A1 | COMBINATION THERAPY FOR REDUCTION OF TOXICITY OF CHEMOTHERAPEUTIC AGENTS | CASCADE ESTATE LTD. (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | METABASIS THERAPEUTICS, INC. | 2008-05-29 | — | — | US | disclosed |
| EP-1923063-A2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7351399-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070249564-A1 | Novel phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070021388-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-01-25 | — | — | US | disclosed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060234982-A1 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. | 2006-10-19 | — | — | US | disclosed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060128692-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC (US) | 2006-06-15 | — | — | US | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1634886-A2 | Novel phosphorus-containing prodrug | Metabasis Therapeutics, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | ERION MARK D | 2005-12-29 | — | — | US | disclosed |
| US-6946115-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-09-30 | — | — | US | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2000016754-A3 | ANTIVIRAL COMBINATIONS COMPRISING LAMIVUDINE AND LOBUCAVIR | GLAXO GROUP LTD (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000016754-A2 | ANTIVIRAL COMBINATIONS COMPRISING LAMIVUDINE AND LOBUCAVIR | GLAXO GROUP LIMITED (GB) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000016754-A2 | ANTIVIRAL COMBINATIONS COMPRISING LAMIVUDINE AND LOBUCAVIR | GLAXO GROUP LIMITED (GB) | 2000-03-30 | — | — | WO | disclosed |
| US-5874578-A | Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process | BRISTOL-MYERS SQUIBB (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0433897-B1 | Process for preparing an optically active cyclobutane nucleoside | SQUIBB & SONS INC (US) | 1997-10-01 | — | — | EP | disclosed |
| EP-0335355-B1 | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines | SQUIBB & SONS INC (US) | 1997-10-01 | — | — | EP | disclosed |
| US-5608064-A | Purinyl salts useful for preparing guanine containing antiviral agents | BRISTOL-MYERS SQUIBB CO. (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0736533-A1 | Intermediates and process for the preparation of an antiviral agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0736533-A1 | Intermediates and process for the preparation of an antiviral agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0535448-B1 | Process and intermediates for the preparation of an antiviral agent containing a cyclobutyl group | SQUIBB & SONS INC (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5525726-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1996-06-11 | — | — | US | disclosed |
| EP-0458643-B1 | Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside | SQUIBB & SONS INC (US) | 1995-11-29 | — | — | EP | disclosed |
| US-5412134-A | Process for preparing diprotected 2,3-hydroxymethyl cyclobutanol | E. R. SQUIBB & SONS, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5399775-A | Process for preparing substituted cyclobutanes | BRISTOL-MYERS SQUIBB CO. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5344962-A | Intermediates in the synthesis of an optically active cyclobutane nucleoside | E. R. SQUIBB & SONS, INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5312963-A | Process for preparing substituted cyclobutanes | BRISTOL-MYERS SQUIBB CO. (US) | 1994-05-17 | — | — | US | disclosed |
| US-5306837-A | Intermediates for an optically active cyclobutane nucleoside | E. R. SQUIBB & SONS, INC. (US) | 1994-04-26 | — | — | US | disclosed |
| EP-0579421-A2 | Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process | E.R. Squibb & Sons, Inc. (US) | 1994-01-19 | — | — | EP | disclosed |
| EP-0572209-A2 | Process for preparing diprotected 2,3-hydroxymethyl cyclobutanol | E.R. SQUIBB & SONS, INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| US-5256806-A | Intermediates for the preparation of optically active cyclobutane nucleoside | E. R. SQUIBB & SONS, INC. (US) | 1993-10-26 | — | — | US | disclosed |
| US-5256806-A | Intermediates for the preparation of optically active cyclobutane nucleoside | E. R. SQUIBB & SONS, INC. (US) | 1993-10-26 | — | — | US | disclosed |
| US-5237095-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5237095-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5237096-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5237096-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5235052-A | PROCESS FOR PREPARING SUBSTITUTED CYCLOBUTANE PURINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| US-5233086-A | Intermediates for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-03 | — | — | US | disclosed |
| US-5233086-A | Intermediates for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-03 | — | — | US | disclosed |
| JP-H05178857-A | PREPARATION OF OPTICALLY ACTIVE CYCLOBUTANE NUCLEOSIDE | E R SQUIBB & SONS INC | 1993-07-20 | — | — | JP | disclosed |
| US-5218142-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5218142-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0535448-A2 | Process and intermediates for the preparation of an antiviral agent containing a cyclobutyl group | E.R. SQUIBB & SONS, INC. (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5198583-A | Optically active cyclobutane nucleoside and intermediates, therefor | E. R. SQUIBB & SONS, INC. (US) | 1993-03-30 | — | — | US | disclosed |
| US-5130462-A | Intermediates for viricides | E. R. SQUIBB & SONS, INC. (US) | 1992-07-14 | — | — | US | disclosed |
| US-5126345-A | Viricides | E. R. SQUIBB & SONS, INC. (US) | 1992-06-30 | — | — | US | disclosed |
| EP-0458643-A2 | Process for preparing an optically active cyclobutanone, an intermediate in the synthesis of an optically active cyclobutane nucleoside | E.R. SQUIBB & SONS, INC. (US) | 1991-11-27 | — | — | EP | disclosed |
| US-5064961-A | PROCESS FOR PREPARING AN OPTICALLY ACTIVE CYCLOBUTANE NUCLEOSIDE | E. R. SQUIBB & SONS, INC. (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0452729-A1 | Process for preparing substituted cyclobutanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-10-23 | — | — | EP | disclosed |
| EP-0433897-A2 | Process for preparing an optically active cyclobutane nucleoside | E.R. SQUIBB & SONS, INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0433897-A2 | Process for preparing an optically active cyclobutane nucleoside | E.R. SQUIBB & SONS, INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0335355-A2 | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines | E.R. Squibb & Sons, Inc. (US) | 1989-10-04 | — | — | EP | disclosed |
| EP-0335355-A2 | Bis-(hydroxymethyl) cyclobutyl purines and pyrimidines | E.R. Squibb & Sons, Inc. (US) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (31 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | PYGL, ALPI, SLC10A1 | HPRT1 227/4885ADORA3 639/4885PNP 14/4885 |
| US-20060128692-A1 | Non nucleoside reverse transcriptase inhibitors | TYMP, PNP, ITPA | HPRT1 56/4885ADORA3 1844/4885PNP 2/4885 |
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | TYMP, MTAP, PNP | HPRT1 24/4885ADORA3 1712/4885PNP 3/4885 |
| US-20130035313-A1 | Nucleoside Phosphonate Salts | NTPCR, NHERF1, SLC29A1 | HPRT1 34/4885ADORA3 35/4885PNP 9/4885 |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | HCRTR2, CYP2R1, SLC22A8 | HPRT1 1531/4885ADORA3 118/4885PNP 599/4885 |
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | HPRT1 579/4885ADORA3 2920/4885PNP 11/4885 |
| US-20070249564-A1 | Novel phosphorus-containing prodrugs | PYGL, ALPI, SLC10A1 | HPRT1 227/4885ADORA3 639/4885PNP 14/4885 |
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | HPRT1 29/4885ADORA3 1636/4885PNP 47/4885 |
| US-20170273994-A1 | Compositions and Methods for Combination Antiviral Therapy | DCTD, TYMP, MTAP | HPRT1 60/4885ADORA3 657/4885PNP 9/4885 |
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | TPMT, HAVCR2, REV1 | HPRT1 5/4885ADORA3 988/4885PNP 718/4885 |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | HPRT1 227/4885ADORA3 639/4885PNP 14/4885 |
| US-20140213556-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | DCTD, TYMP, TYMS | HPRT1 60/4885ADORA3 571/4885PNP 10/4885 |
| US-20060234982-A1 | Compositions and methods for combination antiviral therapy | TYMS, TYMP, MTAP | HPRT1 10/4885ADORA3 151/4885PNP 4/4885 |
| US-20130072460-A1 | Methods Of Treating Retroviral Infections And Related Dosage Regimes | HAVCR2, TPMT, REV1 | HPRT1 4/4885ADORA3 1203/4885PNP 740/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | HPRT1 73/4885ADORA3 2483/4885PNP 2/4885 |
| US-20160158259-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | TPMT, HAVCR2, REV1 | HPRT1 5/4885ADORA3 988/4885PNP 718/4885 |
| US-20080194554-A1 | Hiv Protease Inhibitors | PREP, DNPEP, ANPEP | HPRT1 572/4885ADORA3 2969/4885PNP 121/4885 |
| US-20080194523-A1 | Hiv Integrase Inhibitors | ING2, API5, SAMHD1 | HPRT1 32/4885ADORA3 1661/4885PNP 50/4885 |
| US-20170232019-A1 | Compositions and Methods for Combination Antiviral Therapy | DCTD, TYMP, MTAP | HPRT1 60/4885ADORA3 657/4885PNP 9/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | HPRT1 73/4885ADORA3 2483/4885PNP 2/4885 |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | TYMP, PNP, ITPA | HPRT1 56/4885ADORA3 1844/4885PNP 2/4885 |
| US-20080193408-A1 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | TOP2A, FOLR1, TOP1 | HPRT1 654/4885ADORA3 3243/4885PNP 944/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | HPRT1 1443/4885ADORA3 303/4885PNP 159/4885 |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, CYP2F1 | HPRT1 249/4885ADORA3 430/4885PNP 1/4885 |
| US-20150111856-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | DCTD, TYMP, TYMS | HPRT1 60/4885ADORA3 571/4885PNP 10/4885 |
| US-20070021388-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, TYMP | HPRT1 241/4885ADORA3 401/4885PNP 1/4885 |
| US-20090036408-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | DCTD, TYMP, TYMS | HPRT1 60/4885ADORA3 571/4885PNP 10/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | HPRT1 227/4885ADORA3 639/4885PNP 14/4885 |
| US-20150111855-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | DCTD, TYMP, TYMS | HPRT1 60/4885ADORA3 571/4885PNP 10/4885 |
| US-20110021464-A1 | METHODS OF TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCR5 | HPRT1 72/4885ADORA3 856/4885PNP 244/4885 |
| US-20150203519-A1 | NUCLEOSIDE PHOSPHONATE SALTS | NTPCR, NHERF1, SLC28A1 | HPRT1 32/4885ADORA3 54/4885PNP 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.